Background/aims Intravitreal injection (IVT) of anti-vascular endothelial growth factor agents is the standard of care for several retinal diseases but can cause intraocular pressure (IOP) elevations. This study investigates short-term postinjection IOP changes following aflibercept 8 mg and faricimab, compared with aflibercept 2 mg. Methods This observational, prospective study included 90 patients with age-related macular degeneration or diabetic macular oedema, divided into three groups, receiving aflibercept 2 mg, aflibercept 8 mg or faricimab. IOP was measured using an iCare IC200-tonometer preinjection (T0) and at 30 s (T1), 5 min (T2) and 15 min (T3) postinjection. Primary outcomes included IOP changes at the four time points within and between treatment groups. The incidence of transient visual loss requiring paracentesis was recorded. Results All groups experienced a significant IOP increase at T1, with mean IOP increase being 41.47±12.95 mm Hg for aflibercept 2 mg, 43.46±8.97 mm Hg for aflibercept 8 mg and 32.19±11.06 mm Hg for faricimab. By T2, IOP differences were not significant, and by T3, mean IOP returned within normal limits across all groups. Faricimab showed a smaller initial IOP spike than both aflibercept formulations, but this difference was not statistically significant at T2 and T3. Conclusion Transient IOP spikes are observed post-IVT of aflibercept 8 mg and faricimab, with similar trends to aflibercept 2 mg. The initial IOP elevation normalised within 15 min. Faricimab had a lower initial spike, but overall IOP profiles were comparable across different agents. Data are available on reasonable request.

中文翻译：

---

玻璃体内注射阿柏西普 2 mg、阿柏西普 8 mg 和 faricimab 后短期眼压变化：一项前瞻性比较研究


背景/目标 玻璃体内注射 （IVT） 抗血管内皮生长因子药物是多种视网膜疾病的标准护理，但可导致眼压 （IOP） 升高。本研究调查了阿柏西普 8 mg 和 faricimab 与阿柏西普 2 mg 相比注射后短期眼压变化。方法 这项观察性、前瞻性研究包括 90 名年龄相关性黄斑变性或糖尿病性黄斑水肿患者，分为三组，接受阿柏西普 2 mg、阿柏西普 8 mg 或 faricimab。使用 iCare IC200 眼压计注射前 （T0） 和注射后 30 秒 （T1） 、 5 分钟 （T2） 和 15 分钟 （T3） 测量 IOP。主要结局包括治疗组内和治疗组之间 4 个时间点的 IOP 变化。记录需要穿刺术的短暂性视力丧失的发生率。结果 各组大鼠在 T1 时眼压显著升高，阿柏西普 2 mg 平均眼压升高 41.47±12.95 mm Hg，阿柏西普 8 mg 平均升高 43.46±8.97 mm Hg，faricimab 平均升高 32.19±11.06 mm Hg。到 T2 时，IOP 差异不显著，到 T3 时，所有组的平均 IOP 返回正常范围内。Faricimab 的初始 IOP 峰值小于两种阿柏西普制剂，但这种差异在 T2 和 T3 时无统计学意义。结论 阿柏西普 8 mg 和 faricimab 在 IVT 后观察到短暂的 IOP 峰值，与阿柏西普 2 mg 的趋势相似。初始眼压升高在 15 分钟内恢复正常。Faricimab 的初始峰值较低，但不同药物的总体 IOP 曲线相当。数据可应合理要求提供。